Netherlands: Health Secy Visits Bilthoven Biologicals, Discusses Collaboration On Production Of Oral Polio Vaccine

New Delhi: Union Health Secretary Apurva Chandra on Wednesday visited the manufacturing unit of global pharmaceutical company Bilthoven Biologicals at Utrecht, Netherlands.

Further, the Union Health Secretary met with CEO Juergen Kwik and CEO of Poonawalla Science Park (PSP) at Bilthoven Jef De Clercq on EU pandemic preparedness partnership and collaboration on production of vaccines, the Ministry of Health and FamilyWelfare said in a Press release.

“She also met the senior management and was briefed on the various manufacturing units of the facility. A detailed presentation was made on their future manufacturing plans. Bilthoven Biologicals BV Co manufactures pharmaceutical products such as vaccines for polio, diphtheria-tetanus-polio, and tetanus along with bacillus calmette-guerin (BCG) ,” the press release added.

The bioengineering and vaccine production firm Bilthoven Biologicals was purchased by Serum India Ltd., in 2012. This has strengthened its capacity of producing vaccines and also provided it with a valuable manufacturing base in Europe.

Recently Serum and Bharat Biotech have announced collaboration for enhanced production of OPV. Bharat Biotech will collaborate with Netherlands-based Bilthoven Biologicals BV, a wholly-owned arm of Serum Institute of India.

According to a press release, an agreement has been signed under which Bharat Biotech will procure drug substances for manufacturing oral polio vaccines to be supplied within India and globally. This will contribute to supply security of oral polio vaccines. With this partnership, the capacity of BBIL to manufacture Oral Polio Vaccine (OPV) has increased to 500 million doses every year.

Universal Immunisation Programme (UIP) of the Union Health Ministry is one of the key interventions for protection of children from life threatening conditions by providing vaccination, including vaccine against polio. India has been certified free of Polio in March 2014.However, to maintain the polio-free status, polio vaccine is given to children as part of the high quality national and sub-national polio rounds across the country.

A sustained supply of OPV is essential for keeping India polio free. The partnership between BBIL and Serum will contribute to providing a sustained supply of OPV in the country.

Related Posts

  • Pharma
  • June 27, 2025
  • 132 views
Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world’s first malaria vaccine for children ‘RTS,S’ developed by GSK, PATH and partners,…

  • Pharma
  • June 27, 2025
  • 119 views
Sun Pharma ropes in Richard Ascroft as North America CEO

Mumbai: Sun Pharma has announced the appointment of Richard Ascroft as the new North America (NAM) Chief Executive Officer (CEO). In a statement shared via LinkedIn, the company said, “We…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

MedTech Zone AMTZ Puts Vizag on the Science Map of India

MedTech Zone AMTZ Puts Vizag on the Science Map of India

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Sun Pharma ropes in Richard Ascroft as North America CEO

Sun Pharma ropes in Richard Ascroft as North America CEO

Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen

Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen